FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.
IPO Year:
Exchange: NASDAQ
Website: fsdpharma.com
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K/A - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)
6-K - FSD Pharma Inc. (0001771885) (Filer)